bpc 157 cjc 1295: Frequently asked questions

Administer the missed dose as soon as you remember, then continue your regular schedule. BPC-157's 4-hour half-life means missing one dose creates a 4–8 hour gap in angiogenic signaling, but the cumulative tissue repair effect is what matters over 8–12 weeks. Missing a single dose won't derail the protocol. Missing three or more doses per week will. If you're running twice-daily BPC-157 and consistently miss the second daily dose, drop to once-daily dosing at a higher concentration (500mcg instead of 250mcg twice) rather than maintaining an inconsistent twice-daily schedule.

Don't. Administering BPC-157 and CJC-1295 simultaneously wastes the temporal synergy between them. CJC-1295's mechanism is to raise systemic IGF-1 over 24–48 hours. If you inject BPC-157 at the same moment, its angiogenic effects peak before IGF-1 has risen meaningfully. Stagger the peptides: CJC-1295 first (Monday and Thursday), then daily BPC-157 starting 24–48 hours after the first CJC-1295 dose. That schedule ensures elevated IGF-1 is present when BPC-157 creates new vascular structures requiring collagen support.

Pain reduction is subjective and not the primary marker of tissue repair. BPC-157's angiogenic mechanism creates vascular scaffolding first. Collagen deposition and cross-linking follow weeks later. Some injury types (ligament tears, chronic tendinopathy) show delayed symptomatic improvement because the new tissue must reach load-bearing capacity before pain resolves. If you're three weeks into the BPC-157 CJC-1295 stack with no subjective improvement, verify your dosing schedule (CJC-1295 twice weekly, BPC-157 daily), confirm injection sites are within 2–3 inches of the injury, and continue the protocol to at least week 8 before concluding it's ineffective.

Administer your next dose on the staggered schedule without adjusting total weekly amounts. Simultaneous dosing won't cause harm but eliminates the synergistic timing advantage. You'll still get systemic GH elevation and localized BPC-157 effects, just without the coordinated vascular priming that staggered protocols provide. One mistimed dose doesn't negate a protocol; consistent separation over subsequent administrations restores the intended kinetic alignment.

Discard it. Peptide bonds undergo thermal denaturation at ambient temperature, and DAC-modified peptides are particularly susceptible to aggregation once removed from cold storage. There's no reliable home test for potency loss. The solution may look clear and normal while containing inactive misfolded protein. The financial loss of one vial is vastly preferable to running an entire protocol on degraded compound. Real Peptides includes temperature-sensitive indicators on shipments specifically to catch this issue before reconstitution.

Skip the missed BPC-157 dose and continue with CJC-1295 as scheduled. Do not double-dose BPC-157 to 'catch up'. CJC-1295's multi-day systemic effect isn't dependent on same-day BPC-157 priming, and the subsequent BPC-157 doses will still coordinate with the elevated IGF-1 window. Missing one BPC-157 administration in a twice-daily protocol reduces cumulative VEGF exposure slightly but doesn't compromise the overall combine BPC-157 CJC-1295 synergy dosing timing strategy.